ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received November 13, 2016
- Accepted in final form January 3, 2017
- First Published March 14, 2017.
Author Disclosures
- Peter Körtvélyessy, MD*,
- Markus Breu, MD*,
- Marc Pawlitzki, MD,
- Imke Metz, MD,
- Hans-Jochen Heinze, MD,
- Mike Matzke, MD,
- Christian Mawrin, MD,
- Paulus Rommer, MD,
- Gabor G. Kovacs, MD, PhD,
- Christian Mitter, MD,
- Markus Reindl, PhD,
- Wolfgang Brück, MD, PhD,
- Klaus-Peter Wandinger, MD,
- Hans Lassmann, MD, PhD,
- Romana Höftberger, MD‡ and
- Frank Leypoldt, MD, PhD‡
- Peter Körtvélyessy, MD*,
NONE
NONE
Eisai gGmbH Commercial entity travel costs
NONE
NONE
NONE
NONE
Eisai GmbH
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Markus Breu, MD*,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Marc Pawlitzki, MD,
Novartis advisory board
NONE
Novartis, funding for travel to conference 2014-2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Imke Metz, MD,
1) commercial: advisory board for Roche.
NONE
1)commercial: speaker honoraria, travel grants from BiogenIdec, Bayer Healthcare, TEVA, Serono, Novartis, Genzyme.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
research grant from BiogenIdec.
grants from German Ministry for Education and Research (BMBF, ??German Competence Network Multiple Sclerosis?? (KKNMS), Pattern MS/NMO);
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hans-Jochen Heinze, MD,
(1)UKE Hamburg Eppendorf (1)Hertie Institute for Clinical Brain Research (2)Neuro-Nielsen
NONE
NONE
(1) Frontiers in Human Neuroscience
NONE
NONE
NONE
NONE
Vice-speaker German Centre for Neurodegenerative Diseases Vice-speaker center grant “SFB 779”
NONE
NONE
NONE
(2)Deutsche Forschungs Gemeinschaft, DFG (2)BMBF, Bundesministerium f?r Bildung und Forschung (2)SFB 779 (2)Excellence initiative of the state Saxony-Anhalt
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Mike Matzke, MD,
NONE
NONE
(1) Bayer-Schering, funding for travel and speaker honoraria (2) Merck Serono, funding for travel and speaker honoraria (3) Novartis, funding for travel and speaker honoraria (4) Sanofi-Aventis, funding for travel and speaker honoraria (5) Biogen, funding for travel and speaker honoraria (6) TEVA, funding for travel and speaker honoraria
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Novartis (2) Merck Serono
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Mawrin, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Paulus Rommer, MD,
19 Roche, Merck
NONE
NONE
NONE
NONE
NONE
NONE
1) Teva
NONE
NONE
NONE
1) Merck, Roche
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Gabor G. Kovacs, MD, PhD,
Gedeon Richter Plc. pharmaceutical company
NONE
NONE
Acta Neuropathologica, Editorial Board member; Neuropathology & Applied Neurobiology, Editorial Board member; Clinical Neuropathology, Executive Advisory Board.
Anti-alpha-synuclein antibody 5G4; shared Patent with AJ Roboscreen, Germany.
Neuropathology of Neurodegenerative Diseases: A Practical Guide Cambridge University Press 2014.
NONE
NONE
NONE
NONE
NONE
NONE
Federal Ministry of Health, Austria: Austrian Reference Centre for Human Prion Diseases
NONE
FP7 EU Project Develage, grant n? 278486.
NONE
NONE
NONE
NONE
NONE
NONE
- Christian Mitter, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Markus Reindl, PhD,
NONE
NONE
NONE
PLOS ONE, academic editor, 2012,
NONE
NONE
NONE
NONE
NONE
The University Hospital and Medical University of Innsbruck (Austria, Markus Reindl) receive payments for antibody assays (NMDAR, AQP4 and other autoantibodies) and for MOG and AQP4 antibody validation experiments organized by Euroimmun (Luebeck, Germany).
NONE
NONE
(1) This study was supported by a research grant from the Austrian Federal Ministery of Science and Economy (grant BIG WIG MS).
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Wolfgang Brück, MD, PhD,
I serve on the advisory board of Genzyme, Novartis, Biogen and Teva Pharma.
NONE
I received honoraria for oral presentations from Teva, Sanofi, Genzyme, Novartis, Merck-Serono, Biogen, Roche and Bayer in the last 2 years.
I am editorial board member of Acta neuropathologica, Therapeutic Advances in Neurological disorders, Multiple Sclerosis International and Neuropathology and Applied Neurobiology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Teva Pharma, (2) Novartis, (3) Biogen, (4) Genzyme
(1) German Research foundation (DFG SFB TR43): The brain as a target of inflammatory processes, 2008-2015 German ministry for science and education: Competence network multiple sclerosis, 2010-2018 (2) German Ministry for Education and Reserach: Competence Network Multiple Sclerosis, 2009-2018
NONE
Tschira Foundation German Multiple SClerosis Foundation
NONE
NONE
NONE
NONE
NONE
Teva Pharma, expert witness, 2015-2016
- Klaus-Peter Wandinger, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Hans Lassmann, MD, PhD,
NONE
NONE
I have received speaker and travel honoraria for several scientific meetings from Biogen Idec, Novartis, Roche and Teva.
I am member of the Editorial Board of several Journals in the fields of Neurology and Neuroscience.
NONE
NONE
NONE
I have served as a consultant for Biogen Idec and AMGEN.
NONE
NONE
NONE
NONE
Austrian Science Fund, Projects P27744, I 2114;principal investigator; 2014-2017 European Union PITN.GA-316722; Subproject; This funding is not directly related to the respective article
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Romana Höftberger, MD‡ and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Frank Leypoldt, MD, PhD‡
(1) Roche
NONE
(1) Grifols (2) Teva (3) Biogen (4) Fresenius (5) Bayer
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Institute of Laboratory Medicine, University Hospital Schleswig-Holstein Campus Kiel, Germany, commercial antibody testing service, 20%, 2014-2016
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology (P.K., M.P., H.-J.H., M.M.), Institute of Neuropathology (C.M.), University Hospital Magdeburg; German Center for Neurodegenerative Diseases (DZNE) Magdeburg (P.K.), Germany; Institute of Neurology (M.B., G.G.K., R.H.), Department of Pediatric and Adolescent Medicine (M.B.), Department of Neurology (P.R.), Division of Neuroradiology and Musculoskeletal Radiology (C.M.), Department of Biomedical Imaging and Image-guided Therapy, and Department of Neuroimmunology (H.L.), Center for Brain Research, Medical University of Vienna, Austria; Department of Neuropathology (I.M., W.B.), University Medical Center Göttingen; Leibniz Institute for Neurobiology (H.-J.H.), Magdeburg; Department of Neurology (M.M.), MEDIAN NRZ Flechtingen, Germany; Clinical Department of Neurology (M.R.), Innsbruck Medical University, Austria; Neuroimmunology (K.-P.W., F.L.), Institute of Clinical Chemistry, University Hospital Schleswig-Holstein, Kiel/Lübeck; Department of Neurology (K.-P.W.), University Hospital Schleswig-Holstein, Lübeck; and Department of Neurology (F.L.), University Hospital Schleswig-Holstein, Kiel, Germany.
- Correspondence to Dr. Körtvélyessy: peter.koertvelyessy{at}med.ovgu.de
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.